BACKGROUND: Inherited retinal disease represents a significant cause of blindness
INTRODUCTION
Retinal disease represents a significant cause of blindness and visual morbidity worldwide. Given the typical young age of onset, the individual and socioeconomic impacts of inherited retinal disease (IRD) are profound. 1 However, the heterogeneous clinical and genetic nature of IRD poses a major barrier to research. 2 Nonetheless, advances in our understanding of the pathogenic mechanisms of IRD have led to dramatic improvements in both blindness prevention and treatment.
Major developments in gene-specific vision-restoring therapy have been made in recent years. Human trials for RPE65-associated Leber congenital amaurosis (LCA) are now well underway, following successful restoration of vision using replicationdeficient adeno-associated viral vectors in a naturally occurring canine model. [3] [4] [5] Similarly, recombinant viral treatment was successful in treating an animal model of RPGR ORF15-associated X-linked retinitis pigmentosa (RP). 6 This is a rapidly evolving field and recombinant viral therapy is being developed for a number of retinal diseases including Stargardt disease, choroideraemia and retinoschisis. It is clear that many other genetically tailored therapies will be developed in the near future, rapidly increasing the need for the existence of organised and extensive repositories of phenotypic and genetic information of participants affected with these diseases.
Herein, we describe the establishment and evolution of the Australian Inherited
Retinal Disease Register and DNA Bank. This resource represents a solid foundation for a comprehensive Australian repository for (a) phenotypic information obtained from participants affected with an IRD, (b) relationships within families containing visual electrophysiological testing. Generally, at least one member from an IRD pedigree in Western Australia would be referred and clinically screened by this Department. 12 The DMTP was therefore an effective funnel for such patients and was seen as an appropriate starting point for a local IRD register. Consequently, in 1984 pertinent clinical details of RP patients and their relatives were compiled centrally.
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The scope of the register was subsequently broadened to include families with members affected with any form of IRD. All related activities were conducted in accordance to international standards with regard to its quality measures. All relevant procedural protocols, work instructions, participant or family records and referral forms, as well as correspondence, were stored in compliance with DMTP's ISO9001:2008 accredited quality documentation system. All associated processes were subject annually to both internal and external audit.
Participant Selection and Referral:
Participants were referred and recruited into this register via several means. Where the IRD assigned to a family did not strongly indicate the inheritance mode, such as in the case of RP, an inheritance mode was assigned to a family either from the ophthalmologist's medical records or, if this was unavailable, as follows: 1) Autosomal dominant was assigned to a family if it exhibited direct vertical transmission in three successive generations, and where the family did not exhibit consanguinity.
2) Autosomal recessive was assigned to a family if there were multiple affected siblings and unaffected parents or parental consanguinity.
3) X-linked recessive was assigned to a family if there were multiple affected males and/or affected male(s) and female carrier(s) as ascertained by fundoscopic examination and ERG testing.
4)
Isolate was assigned to a family if the proband was the only documented affected member.
5)
Unclassified was assigned to a family if the family history was unknown, or if there were multiple affected members but none of the inheritance modes above applied.
Inheritance modes were further qualified as definite, probable or possible, based on the amount and clarity of available information for the application of the above classification scheme.
If genetic analysis of a participant's or a family's DNA subsequently clarified the inheritance mode of a disease within a family, then that inheritance mode was the one recorded for that participant or family.
The Australian IRD Register and DNA Bank consists of separate but inter-related data entities.
Hardcopy records:
An individual folder for each participant recruited into the register was constructed and stored securely at the SCGH. Files included completed consent forms, clinical request forms, results of electrophysiological tests, and other written, graphical or pictorial information or correspondence relevant to each participant. These files represent the gold standard of data storage for each registrant.
There was no attempt to consistently gather clinical data stored in the files of ophthalmologists for each participant, such as fundus photographs, autofluorescence, OCT, or electrophysiology tracings. Family history and best known diagnosis (with an assigned confidence level) were included as the minimum data set with respect to clinical information. When a participant gave informed consent, that consent included consent for the investigators to seek relevant medical records from eye care providers.
When a cohort was being considered for genetic analysis, additional clinical information was sought from its custodians at that time if it was deemed necessary.
This proved to be the most efficient use of resources.
Electronic records and register database:
A secure Microsoft Access (Microsoft, Redmond, USA) database contains demographic, clinical, visual electrophysiological and psychophysical data, as well as information relating to the collection and analysis of biological samples.
Upon enrolment, each participant was assigned a unique identification code, and demographic data, such as gender, date of birth and contact details, were collected.
Contact details for the participant's ophthalmologist or referring clinician were also recorded.
In the special case of participants recruited from DMTP patients, clinical data were Extracted DNA was stored in two different locations at -40°C. The buffy coat was extracted from the third vial, and stored at -80ºC. Saliva was an alternative source of DNA. Saliva samples were collected using the Oragene Saliva Kit (2ml; Oragene™ DNA Self collection kit OG-500; DNA Genotek Inc., Canada) and DNA was extracted according to the manufacturer's instructions.
For all collected specimens, data regarding availability of DNA, collection date, the source of the DNA (blood or saliva), storage format and location were entered into the electronic IRD database.
All data obtained by DNA genetic analysis were stored in the secure IRD database. A mutation-ID 
Access to the Register and DNA Bank:
All information was entered into the register and all DNA was deposited into the DNA bank by the custodians of the register and DNA bank. 
RESULTS
Demographic details of 4193 participants are currently recorded in the database, and DNA has been obtained from 2873 (68.5%) participants (Table 1) . Approximately 80% of all DNA collected was obtained from peripheral blood samples. Additionally, DNA collected from 95 unrelated individuals with no known family history of retinal disease, and who have been found to have no ocular disease after comprehensive clinical and electrophysiology examination, has also been stored. These additional samples were used as non-retinal disease control participants to help determine the allele frequency of novel, potentially pathogenic variants in our population.
A total of 2195 (52.3%) participants currently reside in Western Australia; however, under half (42.0%) of all DNA samples stored are from people living in Western Australia ( Table 2 ). The rate of DNA collection increased dramatically during 2009, when we commenced specimen collection from participants throughout Australia (Figure 1 ).
DNA was collected from 34 participants resident outside Australia (Table 2) . These participants were blood relatives of probands of Australian families. For these international participants, DNA was collected as saliva using saliva kits and transported to the DNA bank.
Over half ( 
